Drug Trial Radar · NCT02867709
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Last checked: Nov 19, 2026Latest source record: Mar 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,686
Actual
Start
Aug 26, 2016
Primary completion
Jan 25, 2018
Study completion Feb 26, 2018
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 16, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
Conditions
- Migraine, With or Without Aura
Interventions
UbrogepantDrug
Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo-matching UbrogepantDrug
Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Pain Freedom at 2 Hours After Initial DoseTime frame: Baseline (Predose) to 2 hours after initial dose
- Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial DoseTime frame: Baseline (Predose) to 2 hours after initial dose
Locations
109 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Advantage, Inc./Simon Williamson Clinic
Birmingham, Alabama
Clinical Research Advantage, Inc./East Valley Family Physicians, PLC
Chandler, Arizona
St. Joseph's Hospital & Medical Center - Barrow Neurologic Institute (BNI)
Phoenix, Arizona
Clinical Research Advantage, Inc./Central Phoenix Medical Clinic, LLC
Phoenix, Arizona
Mayo Clinic Arizona, May Clinic Scottsdale
Scottsdale, Arizona
Radiant Research Inc.
Tucson, Arizona
Anaheim Clinical Trials, LLC
Anaheim, California
Axiom Research, LLC
Apple Valley, California
Hope Clinical Research
Canoga Park, California
Axiom Research, LLC
Colton, California
Pharmacology Research Institute
Encino, California
Neuro-Pain Medical Center
Fresno, California
California Headache and Balance Center
Fresno, California
Sun Valley Research Center
Imperial, California
Grossmont Center For Clinical Research
La Mesa, California
Pharmacology Research Institute
Los Alamitos, California
California Advanced Neurotherapeutic, Inc.
Los Angeles, California
Cedars Sinai Pain Center
Los Angeles, California
Pharmacology Research Institute
Newport Beach, California
Rancho Cucamonga Clinical Research
Rancho Cucamonga, California
Desert Valley Research
Rancho Mirage, California
George J Rederich MD, Inc
Redondo Beach, California
Artemis Institute For Clinical Research
San Diego, California
Clinical Research Advantage, Inc./Cassidy Medical Group-Vista
Vista, California
Clinicos, LLC
Colorado Springs, Colorado
Colorado Neurological Institute
Englewood, Colorado
Advanced Neurosciences Research, LLC
Fort Collins, Colorado
Georgetown University Hospital
Washington D.C., District of Columbia
Radiant Clinical Research
Washington D.C., District of Columbia
Aventura Neurological Associates
Aventura, Florida
Clinical Research South Florida
Coral Gables, Florida
Avail Clinical Research, LLC
DeLand, Florida
Broward Research Group
Hollywood, Florida
Health Awareness, Inc.
Jupiter, Florida
Neurology Associates, P.A.
Maitland, Florida
LCC Medical Research Institute, LLC
Miami, Florida
Well Pharma Medical Research, Corp.
Miami, Florida
Panax Clinical Research
Miami Lakes, Florida
Suncoast Clinical Research
New Port Richey, Florida
Renstar Medical Research
Ocala, Florida
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.